IL141220A0 - Conjugates of peg-urate oxidase and use thereof - Google Patents

Conjugates of peg-urate oxidase and use thereof

Info

Publication number
IL141220A0
IL141220A0 IL14122099A IL14122099A IL141220A0 IL 141220 A0 IL141220 A0 IL 141220A0 IL 14122099 A IL14122099 A IL 14122099A IL 14122099 A IL14122099 A IL 14122099A IL 141220 A0 IL141220 A0 IL 141220A0
Authority
IL
Israel
Prior art keywords
conjugates
peg
urate oxidase
urate
oxidase
Prior art date
Application number
IL14122099A
Other languages
English (en)
Original Assignee
Mountain View Pharmaceuticals
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals, Univ Duke filed Critical Mountain View Pharmaceuticals
Publication of IL141220A0 publication Critical patent/IL141220A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL14122099A 1998-08-06 1999-08-02 Conjugates of peg-urate oxidase and use thereof IL141220A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13039298A 1998-08-06 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (1)

Publication Number Publication Date
IL141220A0 true IL141220A0 (en) 2002-03-10

Family

ID=22444494

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14122099A IL141220A0 (en) 1998-08-06 1999-08-02 Conjugates of peg-urate oxidase and use thereof
IL141220A IL141220A (en) 1998-08-06 2001-02-01 PEG couplings - urate oxidase and their use
IL183948A IL183948A (en) 1998-08-06 2007-06-14 Peg-urate oxidase conjugates and use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL141220A IL141220A (en) 1998-08-06 2001-02-01 PEG couplings - urate oxidase and their use
IL183948A IL183948A (en) 1998-08-06 2007-06-14 Peg-urate oxidase conjugates and use thereof

Country Status (13)

Country Link
EP (1) EP1100542B1 (da)
JP (3) JP5183836B2 (da)
KR (2) KR100488848B1 (da)
AU (1) AU770014B2 (da)
BR (2) BRPI9917760B8 (da)
CZ (1) CZ303751B6 (da)
HU (2) HU228916B1 (da)
IL (3) IL141220A0 (da)
NZ (1) NZ509595A (da)
PL (2) PL202799B1 (da)
RU (3) RU2278680C2 (da)
TW (1) TW570981B (da)
WO (1) WO2000007629A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL202799B1 (pl) * 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
JP2002524053A (ja) 1998-08-06 2002-08-06 デューク・ユニバーシティー 尿酸オキシダーゼ
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
AU2006203252B8 (en) * 2000-02-10 2009-06-18 Duke University Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP1279406A4 (en) 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
JP2004517804A (ja) 2000-06-28 2004-06-17 メルク・アンド・カンパニー・インコーポレーテッド 心臓血管病の治療法
AU2002345938A1 (en) 2001-06-28 2003-03-03 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004100997A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
SI1625156T1 (sl) 2003-05-12 2013-02-28 Affymax, Inc. Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006110761A2 (en) * 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
HUE052976T2 (hu) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása
EP1883405A4 (en) 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CN101622270B (zh) 2006-04-12 2014-01-01 萨文特医药公司 用阳离子表面活性剂纯化蛋白质的方法
JP4890132B2 (ja) * 2006-07-20 2012-03-07 東洋紡績株式会社 ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ
RU2382048C1 (ru) * 2008-12-25 2010-02-20 Общество С Ограниченной Ответственностью "Фармапарк" Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CA2869557A1 (en) 2012-04-06 2013-10-10 Indus Pharmaceuticals, Inc. Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
CN107614007B (zh) 2015-05-15 2022-03-25 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
CN112980808B (zh) * 2019-12-12 2024-10-29 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
EP4240423A1 (en) 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CN114438047B (zh) * 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
US20240060063A1 (en) 2021-02-10 2024-02-22 Oriental Yeast Co., Ltd. Uricase activator and uric acid measurement reagent
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6301M (da) * 1967-03-29 1968-09-09
US3616231A (en) * 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6031472B2 (ja) * 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
JPS55135590A (en) * 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
JP2002524053A (ja) * 1998-08-06 2002-08-06 デューク・ユニバーシティー 尿酸オキシダーゼ
PL202799B1 (pl) * 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Also Published As

Publication number Publication date
WO2000007629A3 (en) 2000-06-08
JP2002522399A (ja) 2002-07-23
CZ2001317A3 (cs) 2001-07-11
NZ509595A (en) 2004-02-27
BRPI9912974B1 (pt) 2015-08-25
RU2349341C2 (ru) 2009-03-20
BRPI9912974B8 (pt) 2021-05-25
PL202799B1 (pl) 2009-07-31
JP5290901B2 (ja) 2013-09-18
BR9917760B1 (pt) 2014-11-25
HU226294B1 (en) 2008-08-28
PL220873B1 (pl) 2016-01-29
JP2009254376A (ja) 2009-11-05
PL383331A1 (da) 2002-01-28
BRPI9917760B8 (pt) 2021-05-25
RU2278680C2 (ru) 2006-06-27
EP1100542B1 (en) 2005-06-22
AU5251599A (en) 2000-02-28
EP1100542A2 (en) 2001-05-23
BR9912974A (pt) 2001-05-08
HU228916B1 (en) 2013-06-28
KR20010072287A (ko) 2001-07-31
JP5291235B2 (ja) 2013-09-18
IL141220A (en) 2007-09-20
JP5183836B2 (ja) 2013-04-17
HUP0103003A2 (hu) 2001-11-28
HUP0103003A3 (en) 2006-04-28
WO2000007629A2 (en) 2000-02-17
RU2006107111A (ru) 2007-09-20
AU770014B2 (en) 2004-02-12
CZ303751B6 (cs) 2013-04-24
KR100488848B1 (ko) 2005-05-11
TW570981B (en) 2004-01-11
KR100614212B1 (ko) 2006-08-21
IL183948A (en) 2010-11-30
RU2246318C2 (ru) 2005-02-20
PL346224A1 (en) 2002-01-28
RU2004104953A (ru) 2005-07-27
JP2013039139A (ja) 2013-02-28
KR20040088585A (ko) 2004-10-16
IL183948A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
IL183948A0 (en) Conjugates of peg-urate oxidase and use thereof
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
AU7718898A (en) Txu-7-pap immunotoxin and use thereof
AU8967998A (en) Antibiotic-ligand conjugates and methods of use thereof
GB9813271D0 (en) Composition and use
ZA200101933B (en) Novel composition and use
HUP0105411A3 (en) Palladium-substituted bacteriochlorophyll derivatives and use thereof
PL332616A1 (en) Hydoxymethylhexanones as odorising and savourising agents
EG22491A (en) Rest-breaking composition and use thereof
GB9807586D0 (en) Enzymes and their use
GB0318112D0 (en) ›-Secretase enzyme compositions and methods
AU6084598A (en) Antibiotic-ligand conjugates and methods of use thereof
IL120481A0 (en) Combined enzyme composition and its use
GB9911606D0 (en) Composition and use
GB9805172D0 (en) Composition and use
GB9722392D0 (en) Composition and use
GB9714382D0 (en) Enzymes and their use
GB9826250D0 (en) Novel composition and use
GB9824870D0 (en) Novel composition and use
GB9824869D0 (en) Novel composition and use
GB9824867D0 (en) Novel composition and use
GB9824866D0 (en) Novel composition and use
GB9910410D0 (en) Enzymes and uses thereof
EG24062A (en) Novel composition and use
GB9816014D0 (en) Piperidinecarboxamides and their use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed